dr mary claire haver and glp 1 Weightless: A Doctor's Guide to GLP-1 Medications, Sustainable Weight Loss, the Health You Deserve: Salas-Whalen MD, Rocio, MD, Claire: 9780593981207 Books Ep 267 | Dr. Mary

However, some plans may cover Wegovy off-label for patients with both obesity and documented obstructive sleep apnea (OSA)

According to recently published clinical research by Galderma in January 2025, patients using GLP-1 medications frequently report significant facial alterations: Loss of facial volume creating shadowing and hollowness Increased skin laxity and sagging Changes in facial structure and balance Skin appearing less radiant and drier An overall aged appearance beyond their chronological age Dr

Tirzepatide (Zepbound) received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials published in the New England Journal of Medicine (Malhotra et al., 2024)

Tirzepatide activates two pathways rather than one, sometimes producing different gastrointestinal responses in patients whose baseline digestion is already altered